You know, the biopharma world moves incredibly fast. Constant change, constant evolution. It really does. Keeps us on our toes. Exactly. So today we're looking at Teva Pharmaceuticals, specifically ...

Teva is significantly accelerating the growth of its biosimilars business to broaden access to biologic medicines, support more sustainable healthcare systems and strengthen its position as a global ...

Anyone with concerns regarding potential violations of Teva’s Code, policies or laws, can report it to Teva’s Office of Business Integrity (OBI) through the Teva Integrity Hotline at ...

Can you imagine living with a mind that doesn’t feel quite like your own? Diagnosed with schizophrenia and recovering from a severe psychotic episode, Matt thought he'd found his purpose: becoming a ...

At Teva, we’re all in for better health. Our purpose drives everything we do. We are deeply committed to supporting patients today and building a healthier tomorrow for generations to come. As a ...

When clinical psychologist Lesley McCuaig thinks about the financial impact of schizophrenia, she does not only think about healthcare systems or society-wide costs. She also thinks about the early ...

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy Our transformation at a glance. Innovative ...

When Eric was a newly graduated infectious diseases doctor, he saw firsthand the effect of drugs such as azidothymidine (AZT), the first antiretroviral medication used to prevent and treat HIV/AIDS.

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE ...

Four innovative product submissions targeted over the next 5 years. duvakitug (anti-TL1A) Phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis (UC) and ...

Teva hosting investor call today at 8:00 a.m. ET (U.S.) Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary ...

In May 2023, Teva President and CEO Richard Francis revealed the company’s new Pivot to Growth strategy. One year on, its success has been clearly demonstrated by four consecutive quarters of growth ...